nefazodone has been researched along with alprazolam in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Callahan, AM; Ketter, TA; Post, R | 1 |
| Barbhaiya, RH; Dockens, RC; Greene, DS; Kroboth, P; Salazar, DE | 1 |
| Barbhaiya, R; Chaikin, PC; Folan, MM; Kroboth, PD; Lush, RM; Salazar, DE; Shukla, UA | 1 |
| Granda, BW; Grassi, JM; Greenblatt, DJ; Harmatz, JS; Schmider, J; Shader, RI; von Moltke, LL | 1 |
| Ninan, PT | 1 |
| Cheng, KT; DeVane, CL; Donovan, JL; Liston, HL; Markowitz, JS; Risch, SC; Willard, L | 1 |
1 review(s) available for nefazodone and alprazolam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for nefazodone and alprazolam
| Article | Year |
|---|---|
Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Male; Piperazines; Triazoles | 1995 |
Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lorazepam; Male; Mental Recall; Metabolic Clearance Rate; Piperazines; Psychomotor Performance; Triazolam; Triazoles | 1995 |
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
Topics: Administration, Oral; Adult; Alprazolam; Area Under Curve; Breath Tests; Carbon Radioisotopes; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Drug Administration Schedule; Erythromycin; Fluoxetine; Half-Life; Humans; Male; Middle Aged; Molecular Probes; Piperazines; Sertraline; Triazoles; Venlafaxine Hydrochloride | 2004 |
11 other study(ies) available for nefazodone and alprazolam
| Article | Year |
|---|---|
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition.
Topics: Alprazolam; Antidepressive Agents, Second-Generation; Anxiety; Cytochrome P-450 Enzyme Inhibitors; Depression; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Treatment Outcome; Triazoles | 1996 |
Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.
Topics: Alprazolam; Antidepressive Agents; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Piperazines; Triazoles | 1999 |
Pharmacokinetically induced benzodiazepine withdrawal.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Interactions; Female; Humans; Middle Aged; Panic Disorder; Piperazines; Substance Withdrawal Syndrome; Triazoles; Venlafaxine Hydrochloride | 2001 |